EN DE
Watch Contineum Therapeutics, Inc. Class A Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Contineum Therapeutics, Inc. Class A (CTNM) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Contineum Therapeutics, Inc. Class A stock $6.07, price $9.52, that is 36.3% below the price, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CT Contineum Therapeutics, Inc. Class A logo Thin data Nov 7, 2026

Contineum Therapeutics, Inc. Class A

CTNM · US
Very expensive, weak quality

Our calculation puts a fair price 36% below what the stock costs today.

Mixed vs. peers (4/7)
Insiders sold $1.1M (6M)
Fair value $6.07 · Strongly overvalued
Quality 32/100
Weak Growth
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
⚠ Dilution
Watch Contineum Therapeutics, Inc. Class A Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$21.75 $3.40 Fair Value $6.07 Apr 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

31‑month range $3.40 – $21.75 · fair‑value band $4.00 – $7.58 · the $9.52 price screens above the $6.07 fair value. As of Nov 7, 2026.

Follow Contineum Therapeutics, Inc. Class A Common Stock in your weekly email

Every Wednesday you see whether Contineum Therapeutics, Inc. Class A Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.

Show moreShow less

The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.

Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Stock analysis

Contineum Therapeutics, Inc. Class A (CTNM) currently trades at $9.52, while our model-based Fair Value estimate is $6.07, 36% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $4.00 (bear) to $7.58 (bull), the price of $9.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Contineum Therapeutics, Inc. Class A Common Stock reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$60.0M in FY2025.

Key figures

Market cap $357M Small · EPS (TTM) $−1.59 · Return on equity −29.8% · Return on assets (EBIT) −29.3% (5-year average) · Free cash flow −$55.5M · Net cash $67.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 46% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −36%, CTNM screens richer than that median.

Fair Value models

Bear $4.00 Fair Value $6.07 Bull $7.58
Price $9.52 · Downside -36.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $4.71 $7.14 $8.92 52
All 1 models by family
Asset-Based
NCAV (Graham) $4.71 $7.14 $8.92 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 41
Are margins and returns getting better?
Cashflow 28
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 28
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 23
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $1.1M and none bought.

  • SaleCarmine N. StengoneCEO and President, Director6× since Feb 11, 2026: 25,000 shares, avg. $16.06$401,417Sep 8, 202610b5-1 plan
  • SaleDaniel S. LorrainChief Scientific Officer12× since Dec 23, 2025: 76,033 shares, avg. $14.92$1.1MJul 9, 202610b5-1 plan
  • SaleTim WatkinsCMO & Head of Development4× since Dec 29, 2025: 21,666 shares, avg. $14.89$322,526Jun 30, 202610b5-1 plan

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CTNM screens overvalued: fair value 36% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Contineum Therapeutics, Inc. Class A Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −36.3% · Above median
Profitability
Return on assets −21.7% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.37× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs CTNM
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs CTNM
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs CTNM
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs CTNM
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs CTNM
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs CTNM
argenx SE ARGX $927.21 $908.40 −2% vs CTNM
CSL Limited CSL A$200.77 A$183.04 −9% vs CTNM
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs CTNM
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs CTNM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Contineum Therapeutics, Inc. Class A Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Contineum Therapeutics, Inc. Class A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/CTNM

Frequently asked questions

Is Contineum Therapeutics, Inc. Class A (CTNM) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $6.07 versus a price of $9.52, about 36% lower (overvalued).
What is the fair value of CTNM?
Our model-based fair value for Contineum Therapeutics, Inc. Class A is $6.07 (as of Nov 7, 2026), built from audited fundamentals. The current price: $9.52.
What is the quality score of CTNM?
Contineum Therapeutics, Inc. Class A has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Contineum Therapeutics, Inc. Class A (CTNM)?
Our model-based price target is the fair value of $6.07 (as of Nov 7, 2026) from 1 valuation models. Cautious scenario $4.00, optimistic scenario $7.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Contineum Therapeutics, Inc. Class A Common Stock stock forecast for 2026?
Our models put fair value at $6.07, about 36% lower versus a price of $9.52 (overvalued). Cautious scenario $4.00, optimistic scenario $7.58. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Contineum Therapeutics, Inc. Class A (CTNM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Contineum Therapeutics, Inc. Class A it is $6.07 per share (as of Nov 7, 2026), against a price of $9.52. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Contineum Therapeutics, Inc. Class A Common Stock stock overvalued or undervalued in 2026?
As of Nov 7, 2026, CTNM trades above its calculated fair value: price $9.52, fair value $6.07, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTNM?
No. The price is what the market pays today ($9.52); the fair value is what the company's own numbers justify ($6.07). For Contineum Therapeutics, Inc. Class A the two are $3.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Contineum Therapeutics, Inc. Class A Common Stock worth?
The market values Contineum Therapeutics, Inc. Class A at about $357M (market capitalisation, as of Nov 7, 2026). Per share that is $9.52; our models calculate a fair value of $6.07 per share.
What do the bullish and bearish scenarios say about CTNM?
Our models span a range for Contineum Therapeutics, Inc. Class A: cautious scenario $4.00, base $6.07, optimistic $7.58 per share (as of Nov 7, 2026, price $9.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Contineum Therapeutics, Inc. Class A (CTNM)?
Balance-sheet figures for Contineum Therapeutics, Inc. Class A (as of Nov 7, 2026): return on equity −29.8%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is CTNM from its 52-week high?
Contineum Therapeutics, Inc. Class A trades at $9.52, about 46% below its 52-week high of $17.57 and 34% above the low of $7.08 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $6.07 is for.
Which stocks are comparable to Contineum Therapeutics, Inc. Class A Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Contineum Therapeutics, Inc. Class A Common Stock stock attractive at the current price?
The data as of Nov 7, 2026: price $9.52, calculated fair value $6.07 (−36%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CTNM calculated?
We run Contineum Therapeutics, Inc. Class A through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $6.07 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Contineum Therapeutics, Inc. Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Contineum Therapeutics, Inc. Class A (CTNM)?
The closing price on Nov 6, 2026 was $9.52. Our model-based fair value is $6.07, about 36% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Contineum Therapeutics, Inc. Class A Common Stock right now?
The price sits above even our optimistic bull case ($7.58). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($4.00 to $7.58) leaves room in how you read the outcome.

Key figures of Contineum Therapeutics, Inc. Class A

How large is the market capitalisation of Contineum Therapeutics, Inc. Class A (CTNM)?
The market capitalisation of Contineum Therapeutics, Inc. Class A is $357M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Contineum Therapeutics, Inc. Class A (CTNM)?
Earnings per share at Contineum Therapeutics, Inc. Class A are $−1.59. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Contineum Therapeutics, Inc. Class A (CTNM)?
The return on equity (ROE) of Contineum Therapeutics, Inc. Class A is −29.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Contineum Therapeutics, Inc. Class A (CTNM)?
On an EBIT basis the return on assets of Contineum Therapeutics, Inc. Class A is −29.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Contineum Therapeutics, Inc. Class A (CTNM) generate?
The free cash flow of Contineum Therapeutics, Inc. Class A is −$55.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Contineum Therapeutics, Inc. Class A (CTNM) hold?
Contineum Therapeutics, Inc. Class A holds more cash than debt, $67.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Contineum Therapeutics, Inc. Class A Common Stock in the live analysis

One click puts Contineum Therapeutics, Inc. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.